ASX - By Stock
|
NEU |
Re:
Acadia
|
|
lilypily
|
422 |
188K |
28 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
422
|
188K
|
28
|
|
ASX - By Stock
|
COV |
Re:
Ann: Completion of First Triage Test Clinical Validation Study
|
|
lilypily
|
2 |
1.7K |
6 |
07/11/23 |
07/11/23 |
ASX - By Stock
|
2
|
1.7K
|
6
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Neuren adds Prader-Willi syndrome to NNZ-2591 pipeline
|
|
lilypily
|
44 |
16K |
7 |
16/02/21 |
16/02/21 |
ASX - By Stock
|
44
|
16K
|
7
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Neuren adds Prader-Willi syndrome to NNZ-2591 pipeline
|
|
lilypily
|
44 |
16K |
11 |
16/02/21 |
16/02/21 |
ASX - By Stock
|
44
|
16K
|
11
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Trading Halt
|
|
lilypily
|
356 |
126K |
4 |
10/09/20 |
10/09/20 |
ASX - By Stock
|
356
|
126K
|
4
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Positive Top-Line Results in FSGS Phase 2a Clinical Study
|
|
lilypily
|
286 |
87K |
3 |
29/07/20 |
29/07/20 |
ASX - By Stock
|
286
|
87K
|
3
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Positive Top-Line Results in FSGS Phase 2a Clinical Study
|
|
lilypily
|
286 |
87K |
19 |
29/07/20 |
29/07/20 |
ASX - By Stock
|
286
|
87K
|
19
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Trading Halt
|
|
lilypily
|
111 |
44K |
10 |
28/07/20 |
28/07/20 |
ASX - By Stock
|
111
|
44K
|
10
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Trading Halt
|
|
lilypily
|
59 |
17K |
7 |
18/06/20 |
18/06/20 |
ASX - By Stock
|
59
|
17K
|
7
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Neuren to capture substantially greater value after Phase 3
|
|
lilypily
|
96 |
37K |
5 |
05/06/20 |
05/06/20 |
ASX - By Stock
|
96
|
37K
|
5
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Neuren announces changes to leadership team
|
|
lilypily
|
55 |
20K |
0 |
27/05/20 |
27/05/20 |
ASX - By Stock
|
55
|
20K
|
0
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Neuren announces changes to leadership team
|
|
lilypily
|
55 |
20K |
2 |
27/05/20 |
27/05/20 |
ASX - By Stock
|
55
|
20K
|
2
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Neuren announces changes to leadership team
|
|
lilypily
|
55 |
20K |
9 |
27/05/20 |
27/05/20 |
ASX - By Stock
|
55
|
20K
|
9
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Trading Halt
|
|
lilypily
|
85 |
35K |
5 |
20/03/20 |
20/03/20 |
ASX - By Stock
|
85
|
35K
|
5
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Trading Halt
|
|
lilypily
|
85 |
35K |
4 |
20/03/20 |
20/03/20 |
ASX - By Stock
|
85
|
35K
|
4
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Trading Halt
|
|
lilypily
|
85 |
35K |
0 |
20/03/20 |
20/03/20 |
ASX - By Stock
|
85
|
35K
|
0
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Neuren to capture substantially greater value after Phase 3
|
|
lilypily
|
96 |
37K |
3 |
17/03/20 |
17/03/20 |
ASX - By Stock
|
96
|
37K
|
3
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Additional information
|
|
lilypily
|
20 |
9.5K |
1 |
10/03/20 |
10/03/20 |
ASX - By Stock
|
20
|
9.5K
|
1
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Additional information
|
|
lilypily
|
20 |
9.5K |
3 |
10/03/20 |
10/03/20 |
ASX - By Stock
|
20
|
9.5K
|
3
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Additional information
|
|
lilypily
|
20 |
9.5K |
0 |
10/03/20 |
10/03/20 |
ASX - By Stock
|
20
|
9.5K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Appoints New DMX-200 Medical Advisory Board
|
|
lilypily
|
10 |
4.6K |
5 |
06/03/20 |
06/03/20 |
ASX - By Stock
|
10
|
4.6K
|
5
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Appoints New DMX-200 Medical Advisory Board
|
|
lilypily
|
10 |
4.6K |
7 |
06/03/20 |
06/03/20 |
ASX - By Stock
|
10
|
4.6K
|
7
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Compelling results for 2591 dose ranging study in PMS model
|
|
lilypily
|
44 |
21K |
0 |
06/03/20 |
06/03/20 |
ASX - By Stock
|
44
|
21K
|
0
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Compelling results for 2591 dose ranging study in PMS model
|
|
lilypily
|
44 |
21K |
7 |
06/03/20 |
06/03/20 |
ASX - By Stock
|
44
|
21K
|
7
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Compelling results for 2591 dose ranging study in PMS model
|
|
lilypily
|
44 |
21K |
24 |
06/03/20 |
06/03/20 |
ASX - By Stock
|
44
|
21K
|
24
|
|
ASX - By Stock
|
NEU |
Re:
Unbelievable....
|
|
lilypily
|
31 |
13K |
4 |
05/03/20 |
05/03/20 |
ASX - By Stock
|
31
|
13K
|
4
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Commentary on potential benefit to Neuren of RPD designation
|
|
lilypily
|
25 |
9.1K |
1 |
04/03/20 |
04/03/20 |
ASX - By Stock
|
25
|
9.1K
|
1
|
|
ASX - By Stock
|
NEU |
Re:
Ann: 5 Orphan Drug programs and Rett in Phase 3 funded by partner
|
|
lilypily
|
49 |
1.6M |
20 |
03/03/20 |
03/03/20 |
ASX - By Stock
|
49
|
1.6M
|
20
|
|
ASX - By Stock
|
DXB |
Re:
Ann: DMX-200 Treatment Continued Under TGA Special Access Scheme
|
|
lilypily
|
61 |
26K |
10 |
03/03/20 |
03/03/20 |
ASX - By Stock
|
61
|
26K
|
10
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Appendix 4E and 2019 full year accounts
|
|
lilypily
|
95 |
481K |
2 |
28/02/20 |
28/02/20 |
ASX - By Stock
|
95
|
481K
|
2
|
|
ASX - By Stock
|
NEU |
Re:
How long?.
|
|
lilypily
|
143 |
112K |
7 |
18/02/20 |
18/02/20 |
ASX - By Stock
|
143
|
112K
|
7
|
|
ASX - By Stock
|
NEU |
Re:
How long?.
|
|
lilypily
|
143 |
112K |
9 |
18/02/20 |
18/02/20 |
ASX - By Stock
|
143
|
112K
|
9
|
|
ASX - By Stock
|
NEU |
Re:
How long?.
|
|
lilypily
|
143 |
112K |
21 |
14/02/20 |
14/02/20 |
ASX - By Stock
|
143
|
112K
|
21
|
|
ASX - By Stock
|
NEU |
Re:
Trading
|
|
lilypily
|
467 |
2.3M |
0 |
08/02/20 |
08/02/20 |
ASX - By Stock
|
467
|
2.3M
|
0
|
|
ASX - By Stock
|
NEU |
Re:
NEUREN PRIMED
|
|
lilypily
|
21 |
21K |
5 |
07/02/20 |
07/02/20 |
ASX - By Stock
|
21
|
21K
|
5
|
|
ASX - By Stock
|
NEU |
Re:
NEUREN PRIMED
|
|
lilypily
|
21 |
21K |
12 |
07/02/20 |
07/02/20 |
ASX - By Stock
|
21
|
21K
|
12
|
|
ASX - By Stock
|
NEU |
Re:
NEUREN PRIMED
|
|
lilypily
|
21 |
21K |
23 |
07/02/20 |
07/02/20 |
ASX - By Stock
|
21
|
21K
|
23
|
|
ASX - By Stock
|
NEU |
Re:
Ann: 2019 year-end update and 2020 outlook
|
|
lilypily
|
171 |
117K |
7 |
16/01/20 |
16/01/20 |
ASX - By Stock
|
171
|
117K
|
7
|
|
ASX - By Stock
|
DXB Biotech |
Re:
Taylor's Initiation
|
|
lilypily
|
67 |
31K |
5 |
12/12/19 |
12/12/19 |
ASX - By Stock
|
67
|
31K
|
5
|
|
ASX - By Stock
|
NEU |
Re:
Ann: 2019 year-end update and 2020 outlook
|
|
lilypily
|
171 |
117K |
25 |
12/12/19 |
12/12/19 |
ASX - By Stock
|
171
|
117K
|
25
|
|
ASX - By Stock
|
DXB |
Re:
Clinical trial results 2020
|
|
lilypily
|
76 |
34K |
6 |
10/12/19 |
10/12/19 |
ASX - By Stock
|
76
|
34K
|
6
|
|
ASX - By Stock
|
DXB Biotech |
Re:
Taylor's Initiation
|
|
lilypily
|
67 |
31K |
7 |
09/12/19 |
09/12/19 |
ASX - By Stock
|
67
|
31K
|
7
|
|
ASX - By Stock
|
DXB Biotech |
Re:
Taylor's Initiation
|
|
lilypily
|
67 |
31K |
11 |
09/12/19 |
09/12/19 |
ASX - By Stock
|
67
|
31K
|
11
|
|
ASX - By Stock
|
DXB Biotech |
Re:
Taylor's Initiation
|
|
lilypily
|
67 |
31K |
8 |
09/12/19 |
09/12/19 |
ASX - By Stock
|
67
|
31K
|
8
|
|
ASX - By Stock
|
DXB Biotech |
Re:
Taylor's Initiation
|
|
lilypily
|
67 |
31K |
8 |
09/12/19 |
09/12/19 |
ASX - By Stock
|
67
|
31K
|
8
|
|
ASX - By Stock
|
DXB Biotech |
Re:
Taylor's Initiation
|
|
lilypily
|
67 |
31K |
7 |
09/12/19 |
09/12/19 |
ASX - By Stock
|
67
|
31K
|
7
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Trading Halt
|
|
lilypily
|
102 |
34K |
14 |
03/12/19 |
03/12/19 |
ASX - By Stock
|
102
|
34K
|
14
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Patent to 2034 granted in Europe for Neuren's NNZ-2591
|
|
lilypily
|
20 |
14K |
4 |
03/12/19 |
03/12/19 |
ASX - By Stock
|
20
|
14K
|
4
|
|
ASX - By Stock
|
NEU |
Re:
Bell Potter lifts target to A$4.40/Share Vs A$3.75
|
|
lilypily
|
109 |
80K |
4 |
20/11/19 |
20/11/19 |
ASX - By Stock
|
109
|
80K
|
4
|
|
ASX - By Stock
|
NEU |
Rare Paediatric Disease Designation - Newron
|
|
lilypily
|
0 |
700 |
12 |
19/11/19 |
19/11/19 |
ASX - By Stock
|
0
|
700
|
12
|
|